Closed-Loop Insulin Pump Control Using Continuous Glucose Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing insulin delivery systems for diabetes management are prone to inaccuracies, risking hypoglycemic and hyperglycemic events due to manual insulin dose calculation, which can be life-threatening and lead to long-term health complications.
Innovation Solution
A closed-loop system incorporating a medical fluid pump, continuous analyte monitor, and controller with processors to automatically adjust insulin delivery based on real-time data from sensors, including continuous glucose monitors, accelerometers, and inertial measurement units, to maintain optimal blood glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual insulin dose calculation is used, then the system is simple and easy to operate, but the delivery precision and safety are poor
Solution Approach 1:
The patent implements a closed-loop feedback system where continuous glucose monitors provide real-time glucose level data to a controller, which automatically adjusts insulin delivery rates. This feedback mechanism eliminates manual calculation errors and maintains precise insulin delivery by continuously monitoring and responding to actual physiological conditions.
Solution Approach 2:
The system performs self-service by automatically calculating insulin doses and adjusting delivery parameters without requiring manual intervention. The controller processes glucose data, determines appropriate insulin amounts, and executes delivery adjustments autonomously, reducing human error while maintaining system precision.
2Reliability
If manual insulin dose calculation is used, then the device is simple, but the reliability is poor due to hypoglycemic and hyperglycemic risks
Solution Approach 1:
The closed-loop feedback system continuously monitors glucose levels and automatically adjusts insulin delivery to prevent hypoglycemic and hyperglycemic events. The real-time data from continuous glucose monitors enables the controller to respond dynamically to changing physiological conditions, significantly improving safety and reliability.
Solution Approach 2:
The system performs preliminary actions by predicting future glucose trends based on current and historical data, allowing it to proactively adjust insulin delivery before problematic glucose levels occur. This preventive approach enhances reliability by addressing potential issues before they manifest as safety events.
3Measurement precision
If automated closed-loop system is implemented, then the delivery precision and safety are improved, but the device complexity increases
Solution Approach 1:
The automated closed-loop system performs self-service by autonomously executing all insulin delivery decisions without requiring user intervention. The controller automatically processes glucose data, calculates appropriate doses, and adjusts delivery parameters, eliminating the need for users to perform complex calculations or manual adjustments while maintaining high precision.
Solution Approach 2:
The system replaces manual mechanical operations with automated electronic control. Instead of requiring users to manually calculate and adjust insulin doses, the patent employs electronic sensors, processors, and actuators that automatically perform these functions, improving precision while simplifying user interaction to basic system operation.
Data Source
AI summary
A system for at least partial closed-loop control of a medical condition is disclosed. The system includes at least one medical fluid pump. The medical fluid pump including a sensor for determining the volume of fluid pumped by the pump. Also, at least one continuous analyte monitor, and a controller. The controller is in communication with the medical fluid pump and the at least one continuous analyte monitor. The controller includes a processor. The processor includes instructions for delivery of medical fluid based at least on data received from the at least one continuous analyte monitor.